drugset / Trial / NCT00591630
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and rituximab alone in patients with lymphoma who receive a stem cell transplant.
Timeline
- Start
- 2007-11-14
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Comparator | ibritumomab tiuxetan | Monoclonal antibody | 0.4 unknown | Intravenous |
| Comparator | ibritumomab tiuxetan | Monoclonal antibody | 5 unknown | Intravenous |
| Comparator | Cytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 200 mg/m2 | Intravenous |
| Comparator | Melphalan | Small molecule | 140 mg/m2 | Intravenous |
| Comparator | carmustine | Small molecule | 300 mg/m2 | Intravenous |